aclacinomycin

Aclacinomycin A is an anthracycline drug. It sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. It is used in the treatment of cancer.

Aclacinomycin A (Aclarubicin) hydrochloride is a fluorescent molecule and the first described non-peptidic inhibitor with discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Additionally, it is a dual inhibitor of topoisomerase I and II.

Aclacinomycin A (Aclarubicin) is a novel anthracycline antibiotic isolated from Streptomyces galilei with antitumor activity.Aclacinomycin A is an inhibitor of topoisomerases I and II and inhibits RNA activity.Aclacinomycin A has been used in the study of relapsed leukemia and advanced malignant lymphomas.

Antibiotic MA 144M2 is an anthracycline glycoside that inhibits the growth of gram-positive bacteria, e.g. Staphyococcus aureaus, Bacillus subtilis and Sarcina lutea, and inhibits the growth of animal tumors such as leukemia L 1210, P 388 and sarcoma 180. It's produced by fermentation of MA 144-producing strains of streptomyces and by the chemical or enzymatic conversion of aclacinomycin A or cinerubin A.

Antibiotic MA 144M1 is an anthracycline glycoside that inhibits the growth of gram-positive bacteria, e.g. Staphyococcus aureaus, Bacillus subtilis and Sarcina lutea, and inhibits the growth of animal tumors such as leukemia L 1210, P 388 and sarcoma 180. It's produced by fermentation of MA 144-producing strains of streptomyces and by the chemical or enzymatic conversion of aclacinomycin A or cinerubin A.